- MA5-16949 - Invitrogen Antibodies TGFB1 antibody

Submitted references Restoration of Homeostasis in the Tracheal Mucosa After Thyroid Surgery in a Rat Model.

Kim BH, Kim HB, Park JH, Cho CG, Park SW, Lim YS
In vivo (Athens, Greece) 2022 Jan-Feb;36(1):161-169

Ozone combined with doxorubicin exerts cytotoxic and anticancer effects on Luminal-A subtype human breast cancer cell line.

Karagulle OO, Yurttas AG
Revista da Associacao Medica Brasileira (1992) 2022 Apr;68(4):507-513

Establishment of a tumor immune microenvironment-based molecular classification system of breast cancer for immunotherapy.

Zheng X, Li L, Yu C, Yang J, Zhao Y, Su C, Yu J, Xu M
Aging 2021 Nov 11;13(21):24313-24338

Growth hormone induces mitotic catastrophe of glomerular podocytes and contributes to proteinuria.

Nishad R, Mukhi D, Singh AK, Motrapu M, Chintala K, Tammineni P, Pasupulati AK
Cell death & disease 2021 Apr 1;12(4):342

Anticolitic Effect of Berberine in Rat Experimental Model: Impact of PGE2/p38 MAPK Pathways.

Jia L, Xue K, Liu J, Habotta OA, Hu L, Abdel Moneim AE
Mediators of inflammation 2020;2020:9419085

Molecular Signatures of Sinus Node Dysfunction Induce Structural Remodeling in the Right Atrial Tissue.

Roh SY, Kim JY, Cha HK, Lim HY, Park Y, Lee KN, Shim J, Choi JI, Kim YH, Son GH
Molecules and cells 2020 Apr 30;43(4):408-418

IL-10 producing CD8+ T cells in human infection with Leishmania guyanensis.

Bourreau E, Ronet C, Couppié P, Sainte-Marie D, Tacchini-Cottier F, Launois P
Microbes and infection 2007 Jul;9(8):1034-41

Transforming growth factor beta 1 production by CD4+ CD25+ regulatory T cells in peripheral blood mononuclear cells from healthy subjects stimulated with Leishmania guyanensis.

Kariminia A, Bourreau E, Pascalis H, Couppié P, Sainte-Marie D, Tacchini-Cottier F, Launois P
Infection and immunity 2005 Sep;73(9):5908-14

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemical staining of human brain showing labelling of neurons using a TGF BETA monoclonal antibody (Product # MA5-16949)

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 8 Berberine supressing the protein expressions of TGF- beta in colonic tissue of experimental colitis in rats. (a) Colon from the CNTR group (intact group). (b) Colon from the BER group (without ulceration rats). (c) Colon in experimental colitis, untreated group. (d) Colon in BER low dose (25 mg/kg) and experimental colitis, treated group. (e) Colon in BER high dose (50 mg/kg) and experimental colitis, treated group. All the images were taken at a 100x magnification.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 1 GH induces TGF-beta/SMAD pathway in podocytes. A , B qRT-PCR analysis showing the expression of TGF-beta1 in human podocytes treated with or without GH in concentration (100-500 ng/ml) and time- (up to 48 h) dependent manner. mRNA levels were normalized to beta-actin and presented as fold change on the y -axis. Mean +- SD. ( n = 5). **** p < 0.0001 by one-way ANOVA post hoc Dunnett test. C , D Immunoblotting analysis for indicated genes from podocytes treated with GH in concentration (100-500 ng/ml) and time- (up to 48 h) dependent manner. ( n = 3). E Immunofluorescence analysis for TGF-beta1 (purple color) and counterstained with DAPI [4'',6-diamidino-2-phenylindole (blue color)] in podocytes treated with or without GH (500 ng/ml, 48 h). Scale bar = 50 mum, magnification x500. F , G Estimation of TGF-beta1 in conditioned media (CM) from podocytes treated with GH in concentration (100-500 ng/ml) and time- (up to 48 h) dependent manner. Mean +- SD. ( n = 5). H , I SMAD4 luciferase activity in podocytes treated with GH in concentration (100-500 ng/ml) and time- (up to 48 h) dependent manner. Mean +- SD. ( n = 6). F - I **** p < 0.0001 by one-way ANOVA post hoc Dunnet test. J , K qRT-PCR and immunoblotting analysis show TGFBR1 and TGF-beta1 in mice podocytes treated with or without GH (1.5 mg/kg b.w). Mean +- SD. ( n = 3). **** p < 0.0001 by Student''s t test. Each data point represents the average value of mice from each group. n = 6. L Representative images for TGFBR1 a

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 6 Elevated TGF-beta1 signaling and proteinuria correlated in people with DN. A Representative images of immunohistochemical staining for TGFbeta-1 and NICD1 by DAB in the glomerulus sections from nondiabetic (ND; n = 8) and diabetic nephropathy (DN; n = 14) patients. Magnification x630. Scale bar = 20 mum. ( n = 3). NICD1 and TGF-beta1-stained area in glomerulus (right panel) were quantified using ImageJ (NIH) and presented as a dot plot. Mean +- SD. **** p < 0.0001 by Student''s t test. B , C Representative image of H&E stain in glomerular sections from ND and DN groups. Black arrowhead indicates binucleated and detached podocyte. Magnification x630. Scale bar = 20 mum. Zoomed picture emphasizes a binucleated and detached podocyte. D Representative image of MT stain in glomerular sections from ND and DN groups. Magnification x630. Scale bar = 20 mum. MT-stained area in glomerulus was quantified using ImageJ (NIH) and presented as a dot plot. Mean +- SD. **** p < 0.0001 by Student''s t test. E Immunoblotting analysis for TGF-beta1 in the urine samples from ND ( n = 4) and DN groups ( n = 9). IB immunoblot. F Quantification of TGF-beta1 in the urine samples from ND ( n = 8) and DN ( n = 14) groups. Mean +- SD. ** p < 0.001 by Student''s t test. G Urine samples from ND ( n = 4) and DN ( n = 9) were resolved on SDS-PAGE and stained with Coomassie Blue. BSA bovine serum albumin, M protein standard marker. H Nephroseq ( www.nephroseq.org ) analysis comparing HES1, MIKI67, PCN

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 4 Periostin and TGF-beta 1 expression at protein levels in cardiac tissues. (A)Representativeimagesdepictingthe expressionofperiostin,TGF-beta1,andbeta-actinproteinsinvarious myocardial tissues as evaluated by immunoblot (RA, right atrium; LA, left atrium; RV, right ventricle; LV, left ventricle). (B) Expression ofperiostinandTGF-beta1proteinsnormalizedtothatofbeta-actin ispresentedasmean+-SEMinarbitraryunits(A.U. ),forwhich the mean expression in the control (CTL) was defined as 1 (n = 3 for CTL and 5 for the SNX groups; * P < 0.05 and ** P < 0.01 by unpaired t -test).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 Immune-activated and -suppressed status of the tumor niche. ( A ) Co-staining of CD8 and IFN-gamma in immune-activated and -suppressed patients. ( B ) Co-staining of CD8 and granzyme B in immune-activated and -suppressed patient samples. ( C ) Co-staining of CD45 and TGF-beta1 in immune-activated and -suppressed patient samples. ( D ) Co-staining of CD8 and PD-1 in immune-activated and -suppressed patient samples. Scale bar, 100 mum. Abbreviations: Immu-act: immune-activated; Immu-sup: immune-suppressed.

MA5-16949

Antibody data